What question did this study set out to answer?

The aim is to provide an overview of recent advancements in therapeutic delivery technologies as of November 2025.

February 2, 2026

November 2025 therapeutic delivery: industry update

Puntos clave

The aim is to provide an overview of recent advancements in therapeutic delivery technologies as of November 2025.
Reviewed product approvals including DARZALEX FASPRO, KEYTRUDA QLEX, and EYLEA HD.
Discussed acquisitions and collaborations within the industry.
Highlighted positive outcomes from clinical trials conducted by various companies.
Multiple therapeutic products were approved and introduced to the market.
Halozyme acquired Elektrofi, gaining access to new microparticulate technology.
Successful collaborations and positive clinical trial results were reported by companies like EyePoint and Tiziana.

Resumen

November 2025 saw the approval of a number of products which employ a variety of delivery technologies including Johnson and Johnson's DARZALEX FASPRO (with Haloyzyme's ENHAZE), Merck's KEYTRUDA QLEX, and Regeneron's EYLEA HD. It was also a busy month for acquisitions with Halozyme completing the acquisition of Elektrofi which gives it access to the microparticulate technology Hypercon. Halozyme also announced a collaboration with the Dutch company Merus, for the development of a subcutaneous formulation of petosemtamab. Positive clinical trial data was announced for a number of companies including EyePoint, Tiziana, Nasus, and Tonix.

Me gusta

Guardar